Olympus Partners has acquired PAI Pharma, a US-based manufacturer of generic oral liquids. No financial terms were disclosed. Kurt Orlofski serves as CEO of PAI. PAI Pharma has two large manufacturing ...
STAMFORD, Conn., Feb. 13, 2025 /PRNewswire/ -- Olympus Partners has acquired PAI Pharma ("PAI"), the leading developer, manufacturer and distributor of generic oral liquids in both ready-to-dose ...
UroGen Pharma (URGN) highlighted results from a long-term follow-up study with Jelmyto for pyelocalyceal solution, which is FDA approved for ...
4don MSN
FY 2025 revenue forecast has been revised to ¥997.5 billion, considering progress and challenges in China. Adjusted operating profit is projected at ¥174.5 billion, with an adjusted operating margin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback